methotrexate (MTX) and clinical trials Archives

Abstract Number: 524 • ACR/ARP Annual Meeting 2019
A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies
Joel Kremer¹, Filip Van den Bosch ², Andrea Rubbert-Roth ³, Sebastiao Radominski ⁴, Gerd Burmester ⁵, Heidi Camp ⁶, Sebastian Meerwein ⁷, Mark Howard ⁸, Yanna Song ⁹, Sheng Zhong ¹⁰ and Bernard Combe ¹¹, ¹Albany Medical College, Albany, NY, ²Ghent University Hospital, Ghent, Belgium, ³Kantonsspital St. Gallen, St Gallen, Switzerland, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Charité—University Medicine Berlin, Berlin, Germany, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁸AbbVie Inc., North Chicago, ⁹AbbVie Inc., North Chicago, IL, USA, North Chicago, ¹⁰AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ¹¹CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has shown efficacy in patients with rheumatoid arthritis (RA) when combined with methotrexate (MTX) or other conventional synthetic…
Abstract Number: 1438 • ACR/ARP Annual Meeting 2019
Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study
Toshihisa Kojima¹, Shuji Asai ¹, Masahiro Hanabayashi ², Masatoshi Hayashi ³, Nobunori Takahashi ¹, Yachiyo Kuwatsuka ⁴, Masahiko Ando ⁴ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Ichinomiya Municipal Hospital, Ichinomiya, Japan, ³Hayashi Orthopedic Clinic, Nagano, Japan, ⁴Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Biological DMARD (bDMARD) concomitant with methotrexate (MTX) has made great progress in the treatment of rheumatoid arthritis (RA) in these decades. There are various…

Abstracts tagged "methotrexate (MTX) and clinical trials"

A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies

Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study